{"id":"W2995934717","doi":"10.1016/s1470-2045(19)30788-0","title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":796,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"UCLH Biomedical Research Centre; National Institute for Health and Care Research; Seattle Genetics; GlaxoSmithKline; U.S. Department of Veterans Affairs","keywords":"Medicine; Internal medicine; Refractory (planetary science); Population; Multiple myeloma; Discontinuation; Toxicity; Phases of clinical research; Gastroenterology; Oncology; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1334839683588592,"score_gpt":0.452415809330682,"score_spread":0.3189318409718228,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}